CompletedPhase 1NCT03738228
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jyoti S Mayadev, M.DNRG Oncology
- Intervention
- Atezolizumab(drug)
- Enrollment
- 40 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2019 – 2025
Study locations (16)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- Women and Infants Hospital, Providence, Rhode Island, United States
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03738228 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital